Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...

The idea that a man could receive regular exams and still wind up with a late-stage discovery? It doesn’t surprise me at all.

The form of cancer Joe Biden has is one of the most common cancers to affect men. Here are the warning signs to watch out for.

"Historically, the likelihood of survival at five years for men with metastatic hormone-sensitive prostate cancer was low, but with advancements in initial treatment intensification like what we ...

According to the statement, Biden was diagnosed with "prostate cancer ... a "more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management." ...

Former President Joe Biden has been diagnosed with an "aggressive" form of prostate cancer that has spread to his bones. But ...

Here’s what you should know about PSA screening, why medical guidelines vary and why individualized approaches are essential ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Former President Joe Biden has been diagnosed with prostate cancer. The ex-president's office made the announcement over the ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, if any, might work best.